Securities Issuance And Quotation Procedures For Immutep Limited.pdf

1. Rule 2.7: The entity must provide information or documents to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced on 1/7/96, amended several times.

2. Rule 3.10.3: The entity must disclose the principal terms of the securities, including exercise price and expiry date for options, and amount outstanding and due dates for payment for partly paid securities.

3. Rule 3.10.4: The entity must disclose whether the additional securities rank equally in all respects from the date of allotment with an existing class of quoted securities.

4. Rule 3.10.5: The entity must disclose the issue price or consideration for the securities.

5. Appendix 3B: This appendix contains information about the entity's securities, including the number of securities issued, the class of securities, the issue date, and the principal terms of the securities.

The entity, Immutep Limited, provides the following information:

Part 1 - All issues

1. Ordinary Shares: 260,000,000 Ordinary Shares representing 2,600,000 ADS.
2. Warrants: 2,080,000 Warrants to purchase 2,080,000 ADS.

2. Number of securities issued or to be issued: 260,000,000 Ordinary Shares and 2,080,000 Warrants.

3. Principal terms of the securities:
a. Fully Paid Ordinary Shares: The number and class of securities granted are expressed in terms of ordinary shares, but have been granted over American Depositary Shares (ADS) (where one ADS = 100 Ordinary Shares).
b. Warrants: The warrants have an exercise price of US$2.50 per ADS, are exercisable immediately, and will expire on the third anniversary of the effective date of a registration statement covering resale of all of the warrant shares underlying the ADSs issuable upon exercise of the warrants.

4. Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities? No, the warrants will not be quoted.

5. Issue price or consideration: US$2.00 per ADS to raise US$5,200,000.

6. Purpose of the issue: To continue ongoing clinical development of IMP321, to continue preclinical development of IMP761, for general corporate purposes, and to acquire or invest in businesses, products, and technologies that we view as complementary to our own.

7. Eligible entity: Yes, the entity has obtained security holder approval under rule 7.1A.

8. Issue dates: 21 December 2018, to be held by the securities registry agent pending closing under the securities purchase agreement announced to the market on 19 December, 2018.

9. Number of securities quoted on ASX: 3,344,431,629 Ordinary fully paid shares (ASX: IMM).

10. Number and class of all options: 371,445,231 $0.0237, 793,103 $0.057, 1,026,272 $0.040, 8,475,995 $0.025.

11. Number and class of all warrants over NASDAQ listed American Depository Shares: 1,553,718 US$2.50, 2,080,000 US$2.50.

12. Number and class of all performance rights: 5,472,734 NED PRs, 8,533,063 NED PRs, 73,333,333 LTI, 10,000,000 LTI, 7,751,152 LTI.